COMMUNIQUÉS West-GlobeNewswire

Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
17/02/2026
NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that [...]
Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026
17/02/2026
ACTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that it has successfully enrolled 545 patients in its SYMON™ II multicenter clinical study and has made substantial [...]
Salipro Biotech Expands Global Intellectual Property Estate with Key U.S. Patent Grant
17/02/2026
New U.S. patent secures long term protection for the Salipro® platform technologies, extending exclusivity until 2042 and reinforcing the company’s position as a premier partner for drug discovery against challenging [...]
Communiqué de presse : Les données de phase IIb de l’étude d’entretien sur le duvakitug de Sanofi et Teva ont démontré une efficacité durable cliniquement significative dans la colite ulcéreuse et la maladie de Crohn
17/02/2026
Les données de phase IIb de l’étude d’entretien sur le duvakitug de Sanofi et Teva ont démontré une efficacité durable cliniquement significative dans la colite ulcéreuse et la maladie de Crohn Dans l’étude de phase IIb [...]
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
17/02/2026
In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tolerated and safety [...]
BioCryst to Present at Upcoming Investor Conference
17/02/2026
RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the T.D. Cowen 46 th Annual Health Care Conference in [...]
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
17/02/2026
Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, [...]
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
17/02/2026
–Received Positive Pre-Investigational New Drug (“IND”) Written Feedback from the U.S. Food and Drug Administration (“FDA”)– –Clinical Advisory Board (“CAB”) Includes Key Leaders across Neuropsychiatry, Anesthesiology, [...]
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits
17/02/2026
PharmaPack Program to Expand Access to Affordable, FDA-Approved Branded Ophthalmic Therapies NASHVILLE, Tenn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management [...]
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
17/02/2026
WATERTOWN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, [...]
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
17/02/2026
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced [...]
Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services
17/02/2026
Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global [...]
Inventiva reports preliminary 2025¹ fiscal year financial results
17/02/2026
Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits 2 as of December 31, 2025 Revenues of €4.5 million in 2025 Completed a U.S. registered public offering for gross proceeds of [...]
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance
17/02/2026
15% royalty income increase 11% total revenue increase Tripled net cash position Phase 3 program with fosmanogepix progressing as planned Financial guidance FY 2026: Double-digit increase in total revenue and operating [...]
FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference
17/02/2026
Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator advancing toward IND-enabling studies for TRD HEIDELBERG, Germany, Feb. 17, 2026 (GLOBE NEWSWIRE) -- FundaMental Pharma [...]
Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
17/02/2026
Leiden, the Netherlands, February 17, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer 36 th Annual Healthcare Life [...]
Change to the Roche Enlarged Corporate Executive Committee
17/02/2026
Basel, 17 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the appointment of Mark Dawson, M.D., Ph.D., as the new Head of Roche Pharma Research and Early Development (pRED), effective 1 May 2026. [...]
Inventiva publie ses résultats financiers préliminaires pour l’exercice 2025¹
17/02/2026
Trésorerie et équivalents de trésorerie à 99,3 millions d’euros, et 131,6 millions d’euros en dépôts à court terme 2 au 31 décembre 2025 Chiffre d’affaires de 4,5 millions d’euros en 2025 Réalisation d’une offre au [...]
FIRST PATIENT DOSED IN CITRYLL’S IMAGING STUDY EVALUATING DISTRIBUTION AND TARGET ENGAGEMENT OF CIT-013
17/02/2026
PET-based imaging study designed to assess the biodistribution of CIT-013 and associate disease activity with CIT-013 target disposition in participants with rheumatoid arthritis and hidradenitis suppurativa Findings [...]

Pages